Angiotensin II, plasma renin and sodium depletion as determinants of blood pressure response to saralasin in essential hypertension. Article Swipe
Chalemphol Thananopavarn
,
Michael S. Golub
,
Peter Eggena
,
Jack Barrett
,
Mohinder P. Sambhi
·
YOU?
·
· 1980
· Open Access
·
· DOI: https://doi.org/10.1161/01.cir.61.5.920
YOU?
·
· 1980
· Open Access
·
· DOI: https://doi.org/10.1161/01.cir.61.5.920
To evaluate the role of the renin-angiotensin system and sodium depletion in the hypotensive response to 1-sarcosine-8-alanine-angiotensin II (saralasin), 15 male patients with essential hypertension were studied on a diet containing 120 mEq of sodium and 100 mEq of potassium per day. After a 5-day control period, all subjects had a mild pressor response to the saralasin infusion (p less than 0.01). After 5 days of the diuretic metolazone (5 mg/day), eight of the 15 patients had a vasodepressor response; these responders had a significantly greater increase in plasma renin activity and angiotensin II concentrations than did the non-responders. Sodium deficit differed markedly (p less than 0.001) between the two groups (361 +/- 121 mEq (SD) vs 52 +/- 26 mEq sodium, respectively). The addition of spironolactone (400 mg/day) for 5 days resulted in saralasin responsiveness in all but two patients, both of whom had small sodium deficits. Thus, variability in the natriuretic response to diuretics may affect saralasin testing and limit its clinical utility.
Related Topics
Concepts
Saralasin
Medicine
Internal medicine
Endocrinology
Plasma renin activity
Angiotensin II
Renin–angiotensin system
Sodium
Blood pressure
Natriuresis
Chemistry
Organic chemistry
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1161/01.cir.61.5.920
- https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.61.5.920
- OA Status
- bronze
- Cited By
- 10
- References
- 22
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2046293867
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2046293867Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1161/01.cir.61.5.920Digital Object Identifier
- Title
-
Angiotensin II, plasma renin and sodium depletion as determinants of blood pressure response to saralasin in essential hypertension.Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
1980Year of publication
- Publication date
-
1980-05-01Full publication date if available
- Authors
-
Chalemphol Thananopavarn, Michael S. Golub, Peter Eggena, Jack Barrett, Mohinder P. SambhiList of authors in order
- Landing page
-
https://doi.org/10.1161/01.cir.61.5.920Publisher landing page
- PDF URL
-
https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.61.5.920Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.61.5.920Direct OA link when available
- Concepts
-
Saralasin, Medicine, Internal medicine, Endocrinology, Plasma renin activity, Angiotensin II, Renin–angiotensin system, Sodium, Blood pressure, Natriuresis, Chemistry, Organic chemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- References (count)
-
22Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2046293867 |
|---|---|
| doi | https://doi.org/10.1161/01.cir.61.5.920 |
| ids.doi | https://doi.org/10.1161/01.cir.61.5.920 |
| ids.mag | 2046293867 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/6988103 |
| ids.openalex | https://openalex.org/W2046293867 |
| fwci | 1.58735488 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000328 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adult |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000368 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Aged |
| mesh[2].qualifier_ui | Q000031 |
| mesh[2].descriptor_ui | D000804 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | analogs & derivatives |
| mesh[2].descriptor_name | Angiotensin II |
| mesh[3].qualifier_ui | Q000097 |
| mesh[3].descriptor_ui | D000804 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | blood |
| mesh[3].descriptor_name | Angiotensin II |
| mesh[4].qualifier_ui | Q000187 |
| mesh[4].descriptor_ui | D001794 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | drug effects |
| mesh[4].descriptor_name | Blood Pressure |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D004305 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Dose-Response Relationship, Drug |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D004359 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Drug Therapy, Combination |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D006801 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Humans |
| mesh[8].qualifier_ui | Q000097 |
| mesh[8].descriptor_ui | D006973 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | blood |
| mesh[8].descriptor_name | Hypertension |
| mesh[9].qualifier_ui | Q000188 |
| mesh[9].descriptor_ui | D006973 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | drug therapy |
| mesh[9].descriptor_name | Hypertension |
| mesh[10].qualifier_ui | Q000139 |
| mesh[10].descriptor_ui | D007010 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | chemically induced |
| mesh[10].descriptor_name | Hyponatremia |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D007263 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Infusions, Parenteral |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D008297 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Male |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D008788 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Metolazone |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D008875 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Middle Aged |
| mesh[15].qualifier_ui | Q000097 |
| mesh[15].descriptor_ui | D012083 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | blood |
| mesh[15].descriptor_name | Renin |
| mesh[16].qualifier_ui | Q000627 |
| mesh[16].descriptor_ui | D012504 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | therapeutic use |
| mesh[16].descriptor_name | Saralasin |
| mesh[17].qualifier_ui | Q000097 |
| mesh[17].descriptor_ui | D012964 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | blood |
| mesh[17].descriptor_name | Sodium |
| mesh[18].qualifier_ui | Q000627 |
| mesh[18].descriptor_ui | D013148 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | therapeutic use |
| mesh[18].descriptor_name | Spironolactone |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000328 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Adult |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D000368 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Aged |
| mesh[21].qualifier_ui | Q000031 |
| mesh[21].descriptor_ui | D000804 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | analogs & derivatives |
| mesh[21].descriptor_name | Angiotensin II |
| mesh[22].qualifier_ui | Q000097 |
| mesh[22].descriptor_ui | D000804 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | blood |
| mesh[22].descriptor_name | Angiotensin II |
| mesh[23].qualifier_ui | Q000187 |
| mesh[23].descriptor_ui | D001794 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | drug effects |
| mesh[23].descriptor_name | Blood Pressure |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D004305 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Dose-Response Relationship, Drug |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D004359 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Drug Therapy, Combination |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D006801 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Humans |
| mesh[27].qualifier_ui | Q000097 |
| mesh[27].descriptor_ui | D006973 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | blood |
| mesh[27].descriptor_name | Hypertension |
| mesh[28].qualifier_ui | Q000188 |
| mesh[28].descriptor_ui | D006973 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | drug therapy |
| mesh[28].descriptor_name | Hypertension |
| mesh[29].qualifier_ui | Q000139 |
| mesh[29].descriptor_ui | D007010 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | chemically induced |
| mesh[29].descriptor_name | Hyponatremia |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D007263 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Infusions, Parenteral |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D008297 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Male |
| mesh[32].qualifier_ui | Q000627 |
| mesh[32].descriptor_ui | D008788 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | therapeutic use |
| mesh[32].descriptor_name | Metolazone |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D008875 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Middle Aged |
| mesh[34].qualifier_ui | Q000097 |
| mesh[34].descriptor_ui | D012083 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | blood |
| mesh[34].descriptor_name | Renin |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D012504 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Saralasin |
| mesh[36].qualifier_ui | Q000097 |
| mesh[36].descriptor_ui | D012964 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | blood |
| mesh[36].descriptor_name | Sodium |
| mesh[37].qualifier_ui | Q000627 |
| mesh[37].descriptor_ui | D013148 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | therapeutic use |
| mesh[37].descriptor_name | Spironolactone |
| type | article |
| title | Angiotensin II, plasma renin and sodium depletion as determinants of blood pressure response to saralasin in essential hypertension. |
| biblio.issue | 5 |
| biblio.volume | 61 |
| biblio.last_page | 924 |
| biblio.first_page | 920 |
| topics[0].id | https://openalex.org/T13004 |
| topics[0].field.id | https://openalex.org/fields/29 |
| topics[0].field.display_name | Nursing |
| topics[0].score | 0.7998999953269958 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2916 |
| topics[0].subfield.display_name | Nutrition and Dietetics |
| topics[0].display_name | Vitamin K Research Studies |
| topics[1].id | https://openalex.org/T12840 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.7224000096321106 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2727 |
| topics[1].subfield.display_name | Nephrology |
| topics[1].display_name | Renal function and acid-base balance |
| topics[2].id | https://openalex.org/T12494 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.6610000133514404 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2728 |
| topics[2].subfield.display_name | Neurology |
| topics[2].display_name | Alcoholism and Thiamine Deficiency |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776823063 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9700500965118408 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q410298 |
| concepts[0].display_name | Saralasin |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7932502031326294 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7909078001976013 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C134018914 |
| concepts[3].level | 1 |
| concepts[3].score | 0.7073861360549927 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[3].display_name | Endocrinology |
| concepts[4].id | https://openalex.org/C138976137 |
| concepts[4].level | 4 |
| concepts[4].score | 0.7053457498550415 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7201790 |
| concepts[4].display_name | Plasma renin activity |
| concepts[5].id | https://openalex.org/C2908929049 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6708546876907349 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q65963433 |
| concepts[5].display_name | Angiotensin II |
| concepts[6].id | https://openalex.org/C198710026 |
| concepts[6].level | 3 |
| concepts[6].score | 0.6705572605133057 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q898218 |
| concepts[6].display_name | Renin–angiotensin system |
| concepts[7].id | https://openalex.org/C537181965 |
| concepts[7].level | 2 |
| concepts[7].score | 0.5914306044578552 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q658 |
| concepts[7].display_name | Sodium |
| concepts[8].id | https://openalex.org/C84393581 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4524936378002167 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q82642 |
| concepts[8].display_name | Blood pressure |
| concepts[9].id | https://openalex.org/C174459258 |
| concepts[9].level | 3 |
| concepts[9].score | 0.41028666496276855 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q6980232 |
| concepts[9].display_name | Natriuresis |
| concepts[10].id | https://openalex.org/C185592680 |
| concepts[10].level | 0 |
| concepts[10].score | 0.12234759330749512 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[10].display_name | Chemistry |
| concepts[11].id | https://openalex.org/C178790620 |
| concepts[11].level | 1 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[11].display_name | Organic chemistry |
| keywords[0].id | https://openalex.org/keywords/saralasin |
| keywords[0].score | 0.9700500965118408 |
| keywords[0].display_name | Saralasin |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7932502031326294 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.7909078001976013 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/endocrinology |
| keywords[3].score | 0.7073861360549927 |
| keywords[3].display_name | Endocrinology |
| keywords[4].id | https://openalex.org/keywords/plasma-renin-activity |
| keywords[4].score | 0.7053457498550415 |
| keywords[4].display_name | Plasma renin activity |
| keywords[5].id | https://openalex.org/keywords/angiotensin-ii |
| keywords[5].score | 0.6708546876907349 |
| keywords[5].display_name | Angiotensin II |
| keywords[6].id | https://openalex.org/keywords/renin–angiotensin-system |
| keywords[6].score | 0.6705572605133057 |
| keywords[6].display_name | Renin–angiotensin system |
| keywords[7].id | https://openalex.org/keywords/sodium |
| keywords[7].score | 0.5914306044578552 |
| keywords[7].display_name | Sodium |
| keywords[8].id | https://openalex.org/keywords/blood-pressure |
| keywords[8].score | 0.4524936378002167 |
| keywords[8].display_name | Blood pressure |
| keywords[9].id | https://openalex.org/keywords/natriuresis |
| keywords[9].score | 0.41028666496276855 |
| keywords[9].display_name | Natriuresis |
| keywords[10].id | https://openalex.org/keywords/chemistry |
| keywords[10].score | 0.12234759330749512 |
| keywords[10].display_name | Chemistry |
| language | en |
| locations[0].id | doi:10.1161/01.cir.61.5.920 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S116251202 |
| locations[0].source.issn | 0009-7322, 1524-4539 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0009-7322 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Circulation |
| locations[0].source.host_organization | https://openalex.org/P4310315671 |
| locations[0].source.host_organization_name | Lippincott Williams & Wilkins |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315671 |
| locations[0].license | |
| locations[0].pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.61.5.920 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Circulation |
| locations[0].landing_page_url | https://doi.org/10.1161/01.cir.61.5.920 |
| locations[1].id | pmid:6988103 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Circulation |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/6988103 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5023404144 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Chalemphol Thananopavarn |
| authorships[0].affiliations[0].raw_affiliation_string | C Thananopavarn |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | C Thananopavarn |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | C Thananopavarn |
| authorships[1].author.id | https://openalex.org/A5030868166 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Michael S. Golub |
| authorships[1].affiliations[0].raw_affiliation_string | M S Golub |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | M S Golub |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | M S Golub |
| authorships[2].author.id | https://openalex.org/A5080835143 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Peter Eggena |
| authorships[2].affiliations[0].raw_affiliation_string | P Eggena |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | P Eggena |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | P Eggena |
| authorships[3].author.id | https://openalex.org/A5103459742 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Jack Barrett |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210111250 |
| authorships[3].affiliations[0].raw_affiliation_string | J D Barrett |
| authorships[3].institutions[0].id | https://openalex.org/I4210111250 |
| authorships[3].institutions[0].ror | https://ror.org/01s3wxs84 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210111250 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Barrett Technology (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | J D Barrett |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | J D Barrett |
| authorships[4].author.id | https://openalex.org/A5109923526 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Mohinder P. Sambhi |
| authorships[4].affiliations[0].raw_affiliation_string | M P Sambhi |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | M P Sambhi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | M P Sambhi |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.61.5.920 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Angiotensin II, plasma renin and sodium depletion as determinants of blood pressure response to saralasin in essential hypertension. |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T13004 |
| primary_topic.field.id | https://openalex.org/fields/29 |
| primary_topic.field.display_name | Nursing |
| primary_topic.score | 0.7998999953269958 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2916 |
| primary_topic.subfield.display_name | Nutrition and Dietetics |
| primary_topic.display_name | Vitamin K Research Studies |
| related_works | https://openalex.org/W2397215764, https://openalex.org/W2437581880, https://openalex.org/W1977216511, https://openalex.org/W2071591574, https://openalex.org/W1966545238, https://openalex.org/W2416079590, https://openalex.org/W2025375836, https://openalex.org/W2188566482, https://openalex.org/W2344659913, https://openalex.org/W1980565209 |
| cited_by_count | 10 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1161/01.cir.61.5.920 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S116251202 |
| best_oa_location.source.issn | 0009-7322, 1524-4539 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0009-7322 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Circulation |
| best_oa_location.source.host_organization | https://openalex.org/P4310315671 |
| best_oa_location.source.host_organization_name | Lippincott Williams & Wilkins |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315671 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.61.5.920 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Circulation |
| best_oa_location.landing_page_url | https://doi.org/10.1161/01.cir.61.5.920 |
| primary_location.id | doi:10.1161/01.cir.61.5.920 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S116251202 |
| primary_location.source.issn | 0009-7322, 1524-4539 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0009-7322 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Circulation |
| primary_location.source.host_organization | https://openalex.org/P4310315671 |
| primary_location.source.host_organization_name | Lippincott Williams & Wilkins |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315671 |
| primary_location.license | |
| primary_location.pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.61.5.920 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Circulation |
| primary_location.landing_page_url | https://doi.org/10.1161/01.cir.61.5.920 |
| publication_date | 1980-05-01 |
| publication_year | 1980 |
| referenced_works | https://openalex.org/W2086572717, https://openalex.org/W2062192275, https://openalex.org/W2411422952, https://openalex.org/W1996782227, https://openalex.org/W1976198033, https://openalex.org/W2020000705, https://openalex.org/W2056318483, https://openalex.org/W2005177038, https://openalex.org/W2403608409, https://openalex.org/W1972316794, https://openalex.org/W2394541377, https://openalex.org/W2046418021, https://openalex.org/W2411575883, https://openalex.org/W2315504621, https://openalex.org/W4236834100, https://openalex.org/W1976087398, https://openalex.org/W2011010934, https://openalex.org/W2341792150, https://openalex.org/W2144492790, https://openalex.org/W2339423792, https://openalex.org/W4241605619, https://openalex.org/W2008209156 |
| referenced_works_count | 22 |
| abstract_inverted_index.5 | 63, 130 |
| abstract_inverted_index.a | 28, 43, 50, 77, 83 |
| abstract_inverted_index.(5 | 69 |
| abstract_inverted_index.(p | 58, 103 |
| abstract_inverted_index.15 | 19, 74 |
| abstract_inverted_index.26 | 119 |
| abstract_inverted_index.52 | 117 |
| abstract_inverted_index.II | 17, 93 |
| abstract_inverted_index.To | 0 |
| abstract_inverted_index.in | 11, 87, 133, 136, 150 |
| abstract_inverted_index.of | 4, 33, 38, 65, 72, 125, 142 |
| abstract_inverted_index.on | 27 |
| abstract_inverted_index.to | 15, 54, 154 |
| abstract_inverted_index.vs | 116 |
| abstract_inverted_index.+/- | 112, 118 |
| abstract_inverted_index.100 | 36 |
| abstract_inverted_index.120 | 31 |
| abstract_inverted_index.121 | 113 |
| abstract_inverted_index.The | 123 |
| abstract_inverted_index.all | 47, 137 |
| abstract_inverted_index.and | 8, 35, 91, 160 |
| abstract_inverted_index.but | 138 |
| abstract_inverted_index.did | 96 |
| abstract_inverted_index.for | 129 |
| abstract_inverted_index.had | 49, 76, 82, 144 |
| abstract_inverted_index.its | 162 |
| abstract_inverted_index.mEq | 32, 37, 114, 120 |
| abstract_inverted_index.may | 156 |
| abstract_inverted_index.per | 40 |
| abstract_inverted_index.the | 2, 5, 12, 55, 66, 73, 97, 108, 151 |
| abstract_inverted_index.two | 109, 139 |
| abstract_inverted_index.(361 | 111 |
| abstract_inverted_index.(400 | 127 |
| abstract_inverted_index.(SD) | 115 |
| abstract_inverted_index.both | 141 |
| abstract_inverted_index.day. | 41 |
| abstract_inverted_index.days | 64, 131 |
| abstract_inverted_index.diet | 29 |
| abstract_inverted_index.less | 59, 104 |
| abstract_inverted_index.male | 20 |
| abstract_inverted_index.mild | 51 |
| abstract_inverted_index.role | 3 |
| abstract_inverted_index.than | 60, 95, 105 |
| abstract_inverted_index.were | 25 |
| abstract_inverted_index.whom | 143 |
| abstract_inverted_index.with | 22 |
| abstract_inverted_index.5-day | 44 |
| abstract_inverted_index.After | 42, 62 |
| abstract_inverted_index.Thus, | 148 |
| abstract_inverted_index.eight | 71 |
| abstract_inverted_index.limit | 161 |
| abstract_inverted_index.renin | 89 |
| abstract_inverted_index.small | 145 |
| abstract_inverted_index.these | 80 |
| abstract_inverted_index.0.001) | 106 |
| abstract_inverted_index.0.01). | 61 |
| abstract_inverted_index.Sodium | 99 |
| abstract_inverted_index.affect | 157 |
| abstract_inverted_index.groups | 110 |
| abstract_inverted_index.plasma | 88 |
| abstract_inverted_index.sodium | 9, 34, 146 |
| abstract_inverted_index.system | 7 |
| abstract_inverted_index.between | 107 |
| abstract_inverted_index.control | 45 |
| abstract_inverted_index.deficit | 100 |
| abstract_inverted_index.greater | 85 |
| abstract_inverted_index.mg/day) | 128 |
| abstract_inverted_index.period, | 46 |
| abstract_inverted_index.pressor | 52 |
| abstract_inverted_index.sodium, | 121 |
| abstract_inverted_index.studied | 26 |
| abstract_inverted_index.testing | 159 |
| abstract_inverted_index.activity | 90 |
| abstract_inverted_index.addition | 124 |
| abstract_inverted_index.clinical | 163 |
| abstract_inverted_index.differed | 101 |
| abstract_inverted_index.diuretic | 67 |
| abstract_inverted_index.evaluate | 1 |
| abstract_inverted_index.increase | 86 |
| abstract_inverted_index.infusion | 57 |
| abstract_inverted_index.markedly | 102 |
| abstract_inverted_index.mg/day), | 70 |
| abstract_inverted_index.patients | 21, 75 |
| abstract_inverted_index.response | 14, 53, 153 |
| abstract_inverted_index.resulted | 132 |
| abstract_inverted_index.subjects | 48 |
| abstract_inverted_index.utility. | 164 |
| abstract_inverted_index.deficits. | 147 |
| abstract_inverted_index.depletion | 10 |
| abstract_inverted_index.diuretics | 155 |
| abstract_inverted_index.essential | 23 |
| abstract_inverted_index.patients, | 140 |
| abstract_inverted_index.potassium | 39 |
| abstract_inverted_index.response; | 79 |
| abstract_inverted_index.saralasin | 56, 134, 158 |
| abstract_inverted_index.containing | 30 |
| abstract_inverted_index.metolazone | 68 |
| abstract_inverted_index.responders | 81 |
| abstract_inverted_index.angiotensin | 92 |
| abstract_inverted_index.hypotensive | 13 |
| abstract_inverted_index.natriuretic | 152 |
| abstract_inverted_index.variability | 149 |
| abstract_inverted_index.(saralasin), | 18 |
| abstract_inverted_index.hypertension | 24 |
| abstract_inverted_index.significantly | 84 |
| abstract_inverted_index.vasodepressor | 78 |
| abstract_inverted_index.concentrations | 94 |
| abstract_inverted_index.respectively). | 122 |
| abstract_inverted_index.responsiveness | 135 |
| abstract_inverted_index.spironolactone | 126 |
| abstract_inverted_index.non-responders. | 98 |
| abstract_inverted_index.renin-angiotensin | 6 |
| abstract_inverted_index.1-sarcosine-8-alanine-angiotensin | 16 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.75 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.8034327 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |